Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Direct acting antivirals offer a new opportunity to monitor the immune response in Hepatitis C infection. In this study cytokine markers will be measured during therapy up to time point SVR 12 an correlated to clinical Parameters and regular laboratory findings.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change of IP10 and related cytokines during treatment (ng/ml) | Screening for Biomarkers under DAA Therapy until timepoint SVR 12 (12 weeks treatment plus control 12 weeks after end of Treatment = 24 weeks) | 24 weeks (observation time under and after DAA therapy) |
| Measure | Description | Time Frame |
|---|---|---|
| SVR 12 | Eradication of HCV RNA 12 weeks after end of Treatment (Treatment 12 weeks) | 24 weeks (12 weeks treatment plus control 12 weeks after end of treatment) |
| Change of inflammatory markers (ferritin ng/ml, CRP mg/l, PCT ng/ml) during treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
-
Not provided
Not provided
Patients under DAA therapy > 18 years monocentral.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Georg Peschel | Contact | 00499419447012 | georg.peschel@ukr.de | |
| Kilian Weigand | Contact | 00499419447012 | kilian.weigand@ukr.de |
| Name | Affiliation | Role |
|---|---|---|
| Kilian Weigand | Uiversity of Regensburg | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Regensburg | Recruiting | Regensburg | 93047 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33587435 | Derived | Adenugba A, Hornung M, Weigand K, Peschel G, Junger H, Kupke P, Lang H, Marquardt JU, Zimmermann T, Geissler EK, Schlitt HJ, Werner JM. Ribavirin Improves NK Cell IFNgamma Response During Sofosbuvir-based DAA Therapy in HCV-infected Liver Transplant Recipients. Transplantation. 2021 Oct 1;105(10):2226-2238. doi: 10.1097/TP.0000000000003612. | |
| 29467758 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
Not provided
Not provided
Not provided
Not provided
Not provided
Serum probes
| 24 weeks (observation time under DAA therapy) |
| Hutchinson JA, Weigand K, Adenugba A, Kronenberg K, Haarer J, Zeman F, Riquelme P, Hornung M, Ahrens N, Schlitt HJ, Geissler EK, Werner JM. Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers. Front Immunol. 2018 Feb 7;9:146. doi: 10.3389/fimmu.2018.00146. eCollection 2018. |
| D014777 |
| Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |